Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2009-07-21 20:27:43 UTC |
---|
Update Date | 2014-12-24 20:25:53 UTC |
---|
Accession Number | T3D2900 |
---|
Identification |
---|
Common Name | Propofol |
---|
Class | Small Molecule |
---|
Description | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries. |
---|
Compound Type | - Anesthetic, Intravenous
- Anticonvulsant
- Antiemetic
- Drug
- Free Radical Scavenger
- Hypnotic and Sedative
- Metabolite
- Organic Compound
- Synthetic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | 2,6-Bis(1-methylethyl)phenol | 2,6-Diisopropylphenol | Anepol | Anespro | Anesvan | Critifol | Diisopropylphenol | Diprivan | Disoprivan | Disoprofol | Dormofol | Fresofol | Gobbifol | Hipnolam | Hypro | IV-Pro | Lipuro | Oleo-Lax | Plofed | Profol | Profolen | Propofabb | Propofil | Propofolum | Propogen | Propolipid | Propovan | Propoven | Provive | Rapinovet | Recofol | Safol | Trivam | Troypofol | Unifol |
|
---|
Chemical Formula | C12H18O |
---|
Average Molecular Mass | 178.271 g/mol |
---|
Monoisotopic Mass | 178.136 g/mol |
---|
CAS Registry Number | 2078-54-8 |
---|
IUPAC Name | 2,6-bis(propan-2-yl)phenol |
---|
Traditional Name | propofol |
---|
SMILES | CC(C)C1=CC=CC(C(C)C)=C1O |
---|
InChI Identifier | InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3 |
---|
InChI Key | InChIKey=OLBCVFGFOZPWHH-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as cumenes. These are aromatic compounds containing a prop-2-ylbenzene moiety. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Cumenes |
---|
Direct Parent | Cumenes |
---|
Alternative Parents | |
---|
Substituents | - Phenylpropane
- Cumene
- 1-hydroxy-4-unsubstituted benzenoid
- Phenol
- Organic oxygen compound
- Hydrocarbon derivative
- Organooxygen compound
- Aromatic homomonocyclic compound
|
---|
Molecular Framework | Aromatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | |
---|
Pathways | Not Available |
---|
Applications | |
---|
Biological Roles | Not Available |
---|
Chemical Roles | |
---|
Physical Properties |
---|
State | Liquid |
---|
Appearance | Not Available |
---|
Experimental Properties | Property | Value |
---|
Melting Point | 18°C | Boiling Point | 256°C | Solubility | 124 mg/L | LogP | 3.79 |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-01t9-4900000000-9238ef924bbbfe181bdc | 2017-09-01 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (1 TMS) - 70eV, Positive | splash10-0079-8590000000-6ada855df5d0fd97f0b7 | 2017-10-06 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - Orbitrap 9V, negative | splash10-004i-0900000000-bf525942be4ead264ece | 2020-07-22 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - n/a 12V, negative | splash10-03di-0900000000-3ab0d6afaf938a81d3dd | 2020-07-22 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - n/a 12V, negative | splash10-001i-0900000000-9e57c7a18ce111c12c63 | 2020-07-22 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-004i-0900000000-40f0918750264d7e34e2 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-004i-3900000000-fa9d883374aeb7d58af5 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-01ox-9500000000-08cc06244cce31efd090 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-004i-0900000000-d85c9325119ea81302f8 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-004i-0900000000-d81a7f98827c18689c1d | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-004i-1900000000-40cc01d9032f866dffc1 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-004i-3900000000-e19ef26e49a6f11e7a9c | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-004i-1900000000-41fb115d031fb4201636 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-002f-9300000000-b212a8d5755ad08fa845 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-004i-0900000000-1c420c1b8167732abdd0 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-004i-0900000000-585908487fc3aed582c4 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-02ta-8900000000-f5810de472ff4197dc17 | 2021-10-11 | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-03di-2900000000-52d81dde2dccf378a450 | 2014-09-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 90 MHz, CDCl3, experimental) | Not Available | 2014-09-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 25.16 MHz, CDCl3, experimental) | Not Available | 2014-09-23 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Rapid - time to onset of unconsciousness is 15-30 seconds, due to rapid distribution from plasma to the CNS. Distribution is so rapid that peak plasma concentrations cannot be readily measured. Duration of action is 5-10 minutes. Parenteral (intravenous injection) (12); inhalation (12) ; dermal (12) |
---|
Mechanism of Toxicity | The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid (GABA) through GABA-A receptors. |
---|
Metabolism | Propofol is rapidly distributed into peripheral tissues after absorption. It is highly protein bound in vivo and is metabolised by conjugation in the liver. Propofol is metabolized mainly by glucuronidation by uridine diphosphate-glucuronosyltransferases (UGTs) and by hydroxylation by CYP2B6 and CYP2C enzymes. The enzymes SULT1A1 and NQO1 participate in later steps in propofol metabolism. An unidentified route of extrahepatic metabolism may also exist, suggested by the fact that propofol clearance exceeds estimated hepatic blood flow. (12, 4, 1). Propofol is hepatically metabolized mainly by glucuronidation at the C1-hydroxyl. Hydroxylation of the benzene ring to 4-hydroxypropofol may also occur via CYP2B6 and 2C9 with subsequent conjugation to sulfuric and/or glucuronic acid. Hydroxypropofol has approximately 1/3 of hypnotic activity of propofol.
Route of Elimination: It is chiefly eliminated by hepatic conjugation to inactive metabolites which are excreted by the kidney.
Half Life: Initial distribution phase t1/2α=1.8-9.5 minutes. Second redistirubtion phase t1/2β=21-70 minutes. Terminal elimination phase t1/2γ=1.5-31 hours. |
---|
Toxicity Values | IV LD50=53 mg/kg (mice), 42 mg/kg (rats). Oral LD50 (as a solution in soybean oil)=1230 mg/kg (mice), 600 mg/kg (rats) |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
---|
Uses/Sources | Its widespread use as an anesthetic induction agent has largely replaced that of sodium pentothal. It is also commonly used in veterinary medicine. (12). Used for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Mild myoclonic movements are common, as with other intravenous hypnotic agents. Another recently described rare, but serious, side effect is propofol infusion syndrome. This potentially lethal metabolic derangement has been reported in critically-ill patients after a prolonged infusion of high-dose propofol in combination with catecholamines and/or corticosteroids. Overdose of these agents is likely to cause cardiorespiratory depression. (12, 14) They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive. May cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease. |
---|
Symptoms | Aside from the hypotension (mainly through vasodilatation) and transient apnea following induction doses, one of propofol's most frequent side effects is pain on injection, especially in smaller veins. A more serious but rare side effect is dystonia. |
---|
Treatment | If overdosage occurs, Propofol administration should be discontinued immediately. Overdosage is likely to cause cardiorespiratory depression. Respiratory depression should be treated by artificial ventilation with oxygen. Cardiovascular depression may require repositioning of the patient by raising the patient's legs, increasing the flow rate of intravenous fluids, and administering pressor agents and/or anticholinergic agents. (16) |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB00818 |
---|
HMDB ID | HMDB14956 |
---|
PubChem Compound ID | 4943 |
---|
ChEMBL ID | CHEMBL526 |
---|
ChemSpider ID | 4774 |
---|
KEGG ID | C07523 |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 8495 |
---|
BioCyc ID | Not Available |
---|
CTD ID | Not Available |
---|
Stitch ID | Propofol |
---|
PDB ID | PFL |
---|
ACToR ID | 3040 |
---|
Wikipedia Link | Propofol |
---|
References |
---|
Synthesis Reference | John R. Carpenter, “Propofol-based anesthetic and method of making same.” U.S. Patent US6150423, issued May, 1977. |
---|
MSDS | Link |
---|
General References | - Restrepo JG, Garcia-Martin E, Martinez C, Agundez JA: Polymorphic drug metabolism in anaesthesia. Curr Drug Metab. 2009 Mar;10(3):236-46. [19442086 ]
- Vasile B, Rasulo F, Candiani A, Latronico N: The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003 Sep;29(9):1417-25. Epub 2003 Aug 6. [12904852 ]
- Barann M, Urban B, Stamer U, Dorner Z, Bonisch H, Bruss M: Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis. Eur J Pharmacol. 2006 Feb 15;531(1-3):54-8. Epub 2006 Jan 19. [16427041 ]
- Gunther S, McMillan PJ, Wallace LJ, Muller S: Plasmodium falciparum possesses organelle-specific alpha-keto acid dehydrogenase complexes and lipoylation pathways. Biochem Soc Trans. 2005 Nov;33(Pt 5):977-80. [16246025 ]
- Ke JJ, Zhan J, Feng XB, Wu Y, Rao Y, Wang YL: A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro- and anti-inflammatory cytokines in patients undergoing open cholecystectomy. Anaesth Intensive Care. 2008 Jan;36(1):74-8. [18326136 ]
- Hong JY, Kang YS, Kil HK: Anaesthesia for day case excisional breast biopsy: propofol-remifentanil compared with sevoflurane-nitrous oxide. Eur J Anaesthesiol. 2008 Jun;25(6):460-7. doi: 10.1017/S026502150800375X. Epub 2008 Feb 26. [18298873 ]
- Takahashi O, Hiraga K: 4-tert-butyl-2,6-diisopropylphenol: Another phenol inducing hemorrhage in rats. Toxicol Lett. 1980 Feb;5(2):147-50. [7466839 ]
- Rumack BH (2009). POISINDEX(R) Information System. Englewood, CO: Micromedex, Inc. CCIS Volume 141, edition expires Aug, 2009.
- MICROMEDEX Thomson Health Care (2002). USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. Englewood, CO: MICROMEDEX Thomson Health Care. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc.
- Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206
- Wikipedia. Barium titanate. Last Updated 27 April 2009. [Link]
- Wikipedia. Propofol. Last Updated 9 August 2009. [Link]
- Chemicalland21.com (2009). 2,6-Diisopropylphenol (Propofol). [Link]
- Wikipedia. Tramadol. Last Updated 8 August 2009. [Link]
- Drugs.com [Link]
- RxList: The Internet Drug Index (2009). [Link]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Not Available |
---|
Down-Regulated Genes | Not Available |
---|